Greenwich Lifesciences Inc (GLSI)

$27.21 +1.24 (4.77%)
Market Cap 350.53M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 219,500
Avg Vol 154,224
Day's Range N/A - N/A
Shares Out 13.86M
Stochastic %K 79%
Beta 1.39
Analysts Strong Sell
Price Target $47.50

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy...

Industry: Biotechnology
Sector: Healthcare
Phone: 832 819 3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
Toontje1
Toontje1 May. 15 at 10:17 PM
$GLSI Insider Selling? ZERO. Snehal Patel has never sold a single share since the 2020 IPO. Not at $5, not at $158, not now. Instead, he has bought over 75 times on the open market, owning over 50% of the company. He is confident that this drug works, and I’m sure almost all small biotech CEO’s do know if the drug is likely to fail or likely to deliver some massive gains. The only reason they start a trail is for massive gains(Patel) or for dilution and make themself rich and dilute poor shareholders.
0 · Reply
crypto_biotech
crypto_biotech May. 15 at 8:27 PM
$GLSI
0 · Reply
Machiavellia
Machiavellia May. 15 at 8:10 PM
$GLSI earnings expected today?
1 · Reply
Hbhatwala
Hbhatwala May. 15 at 8:09 PM
$GLSI 239.92% short Interest on fintel……..
1 · Reply
6digitmidget
6digitmidget May. 15 at 8:05 PM
$GLSI great finish for a blah market today.
0 · Reply
Ginelle2424
Ginelle2424 May. 15 at 8:02 PM
$GLSI will be taking the rest of the month off from the charts (currently traveling) but I know she'll be OVER$30 when I'm back.
1 · Reply
icgmc11
icgmc11 May. 15 at 7:56 PM
$GLSI unusual press release on Friday at 5pm? 🤔
2 · Reply
Rolltide2020
Rolltide2020 May. 15 at 7:53 PM
$GLSI Cover your short positions and enjoy your weekend worry free......or don't.
0 · Reply
crypto_biotech
crypto_biotech May. 15 at 7:47 PM
$GLSI Wow!😮
1 · Reply
Rolltide2020
Rolltide2020 May. 15 at 7:33 PM
$GLSI Heating up again.
1 · Reply
Latest News on GLSI
Greenwich LifeSciences says Form 10-K ‘still being audited’

2026-04-30T10:11:17.000Z - 15 days ago

Greenwich LifeSciences says Form 10-K ‘still being audited’

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Apr 30, 2026, 6:00 AM EDT - 15 days ago

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Apr 23, 2026, 6:00 AM EDT - 22 days ago

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Greenwich LifeSciences receives noncompliance notification from Nasdaq

2026-04-22T21:05:16.000Z - 23 days ago

Greenwich LifeSciences receives noncompliance notification from Nasdaq

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 22, 2026, 5:00 PM EDT - 23 days ago

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences presents Flamingo-01 Phase 3 results from AACR 2026

2026-04-20T10:17:19.000Z - 25 days ago

Greenwich LifeSciences presents Flamingo-01 Phase 3 results from AACR 2026

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Apr 20, 2026, 6:00 AM EDT - 25 days ago

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences reports cash balance of $10.5M as of March 31

2026-04-14T10:21:37.000Z - 4 weeks ago

Greenwich LifeSciences reports cash balance of $10.5M as of March 31

Greenwich LifeSciences Provides Update on Financing Strategy

Apr 14, 2026, 6:00 AM EDT - 4 weeks ago

Greenwich LifeSciences Provides Update on Financing Strategy

Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01

2026-04-07T10:06:43.000Z - 5 weeks ago

Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Apr 7, 2026, 6:00 AM EDT - 5 weeks ago

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial

2026-03-19T10:12:27.000Z - 2 months ago

Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Mar 19, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Greenwich LifeSciences provides update on presentations at AACR Meeting 2026

2026-03-18T10:11:20.000Z - 2 months ago

Greenwich LifeSciences provides update on presentations at AACR Meeting 2026

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Mar 18, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial

2026-03-17T10:21:32.000Z - 2 months ago

Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Mar 17, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01

2026-03-16T10:32:26.000Z - 2 months ago

Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Mar 16, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial

2026-03-03T11:05:58.000Z - 2 months ago

Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Mar 3, 2026, 6:00 AM EST - 2 months ago

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Feb 24, 2026, 6:00 AM EST - 2 months ago

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial

2026-01-27T11:11:03.000Z - 3 months ago

Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Jan 27, 2026, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA

2026-01-22T11:21:40.000Z - 4 months ago

Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Jan 22, 2026, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright

2025-12-30T11:10:33.000Z - 4 months ago

Greenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright

Greenwich LifeSciences extends lock-up of directors, officers to September 30

2025-12-29T11:15:15.000Z - 4 months ago

Greenwich LifeSciences extends lock-up of directors, officers to September 30

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Dec 29, 2025, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters

2025-12-22T11:21:11.000Z - 5 months ago

Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters

Greenwich LifeSciences provides update on FLAMINGO-01 trial

2025-12-22T11:15:26.000Z - 5 months ago

Greenwich LifeSciences provides update on FLAMINGO-01 trial

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Dec 22, 2025, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm

2025-12-15T11:16:50.000Z - 5 months ago

Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Dec 15, 2025, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences: Enrollment complete in open label arm oFLAMINGO-01 trial

2025-12-08T11:10:12.000Z - 5 months ago

Greenwich LifeSciences: Enrollment complete in open label arm oFLAMINGO-01 trial

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Dec 8, 2025, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences screens over 1,000 patients in Flamingo-01 cancer trial

2025-12-03T11:16:01.000Z - 5 months ago

Greenwich LifeSciences screens over 1,000 patients in Flamingo-01 cancer trial

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Dec 3, 2025, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Greenwich LifeSciences adds Austria to Flamingo-01 clinical trial

2025-10-09T10:06:03.000Z - 7 months ago

Greenwich LifeSciences adds Austria to Flamingo-01 clinical trial

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Oct 9, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Oct 2, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 30, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 18, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Sep 10, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 20, 2025, 9:25 AM EDT - 9 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 19, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 13, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Aug 11, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 1 year ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 2 years ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Toontje1
Toontje1 May. 15 at 10:17 PM
$GLSI Insider Selling? ZERO. Snehal Patel has never sold a single share since the 2020 IPO. Not at $5, not at $158, not now. Instead, he has bought over 75 times on the open market, owning over 50% of the company. He is confident that this drug works, and I’m sure almost all small biotech CEO’s do know if the drug is likely to fail or likely to deliver some massive gains. The only reason they start a trail is for massive gains(Patel) or for dilution and make themself rich and dilute poor shareholders.
0 · Reply
crypto_biotech
crypto_biotech May. 15 at 8:27 PM
$GLSI
0 · Reply
Machiavellia
Machiavellia May. 15 at 8:10 PM
$GLSI earnings expected today?
1 · Reply
Hbhatwala
Hbhatwala May. 15 at 8:09 PM
$GLSI 239.92% short Interest on fintel……..
1 · Reply
6digitmidget
6digitmidget May. 15 at 8:05 PM
$GLSI great finish for a blah market today.
0 · Reply
Ginelle2424
Ginelle2424 May. 15 at 8:02 PM
$GLSI will be taking the rest of the month off from the charts (currently traveling) but I know she'll be OVER$30 when I'm back.
1 · Reply
icgmc11
icgmc11 May. 15 at 7:56 PM
$GLSI unusual press release on Friday at 5pm? 🤔
2 · Reply
Rolltide2020
Rolltide2020 May. 15 at 7:53 PM
$GLSI Cover your short positions and enjoy your weekend worry free......or don't.
0 · Reply
crypto_biotech
crypto_biotech May. 15 at 7:47 PM
$GLSI Wow!😮
1 · Reply
Rolltide2020
Rolltide2020 May. 15 at 7:33 PM
$GLSI Heating up again.
1 · Reply
yft212
yft212 May. 15 at 7:08 PM
$SLS In a perfect world SLS gets bought out first and then I can roll those profits into $GLSI . It just takes a little PAYtience!
2 · Reply
StockMomentumLab
StockMomentumLab May. 15 at 7:03 PM
$GLSI shorts are playing with fire into the weekend. Borrow fee just crossed INSANE territory — north of 200% annualized on some desks. That means shorting 10k shares here can bleed over $50K/month just in borrow costs ALONE before price action even matters. 👉Click to view @StockMomentumLab for timely updates amid the volatility. Now add the setup: • Thin float • Crowded short positioning • Biotech headline risk • PR window wide open One surprise catalyst and this turns into a full-scale liquidity trap. Shorts aren’t just fighting price… they’re fighting TIME. This is the kind of setup where a single premarket headline can send forced covering into overdrive. Eyes wide open Monday.
0 · Reply
crypto_biotech
crypto_biotech May. 15 at 7:02 PM
$GLSI He is betting on $SLS. I hope he wins or hope SLS treats him well. I always like biotech to win. They will have their Phase 3 results soon. I hope they are great. I have no idea if stats that say it will fail or succeed are accurate. Unsure why he brings up Insider buys or sales on GLSI or why they cross post. Here is Snehal & their CEO… but it doesn’t matter. Good luck to all of us.
1 · Reply
crypto_biotech
crypto_biotech May. 15 at 6:51 PM
$GLSI Sure.
1 · Reply
crypto_biotech
crypto_biotech May. 15 at 6:51 PM
$GLSI Best Insider Buys. Not 1 single sell. Ever. None. Weekend beckons…
0 · Reply
Daryl1689
Daryl1689 May. 15 at 6:45 PM
$GLSI The 55x guy is a ten year scam artist.
1 · Reply
Lukeing_At_Stocks
Lukeing_At_Stocks May. 15 at 6:37 PM
$GLSI
0 · Reply
Stock_profit_03
Stock_profit_03 May. 15 at 6:37 PM
$GLSI Two weeks to ASCO. Lets go Snehal
0 · Reply
Rolltide2020
Rolltide2020 May. 15 at 6:36 PM
$GLSI
0 · Reply
Rolltide2020
Rolltide2020 May. 15 at 6:35 PM
$GLSI Trending
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 6:30 PM
$GLSI @crypto_biotech Loves Snehels catnip... Insider Buys: PUNY - $15K $25K $39K $7K INSIDER FAMILY SELLS: Massive $77M
1 · Reply
Tetroman
Tetroman May. 15 at 6:25 PM
$GLSI reached 29 today wow - somone is pumping 😆
0 · Reply